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Abstract
 
Interleukin (IL)-18 synergizes with IL-12 to promote T helper cell (Th)1 responses. Somewhat
paradoxically, IL-18 administration alone strongly induces immunoglobulin (Ig)E production
and allergic inflammation, indicating a role for IL-18 in the generation of Th2 responses. The
 
ability of IL-18 to induce IgE is dependent on CD4
 
  
 
T cells, IL-4, and signal transducer and ac-
 
tivator of transcription (stat)6. Here, we show that IL-18 fails to induce IgE both in CD1d
 
 
 
/
 
 
 
mice that lack natural killer T (NKT) cells and in class II
 
 
 
/
 
  
 
mice that lack conventional CD4
 
  
 
T
cells. However, class II
 
 
 
/
 
  
 
mice reconstituted with conventional CD4
 
  
 
T cells show the capacity
 
to produce IgE in response to IL-18. NKT cells express high levels of IL-18 receptor (R)
 
  
 
chain
and produce significant amounts of IL-4, IL-9, and IL-13, and induce CD40 ligand expression in
response to IL-2 and IL-18 stimulation in vitro. In contrast, conventional CD4
 
  
 
T cells express
low levels of IL-18R
 
  
 
and poorly respond to IL-2 and IL-18. Nevertheless, conventional CD4
 
 
 
T cells are essential for B cell IgE responses after the administration of IL-18. These findings in-
dicate that NKT cells might be the major source of IL-4 in response to IL-18 administration and
that conventional CD4
 
  
 
T cells demonstrate their helper function in the presence of NKT cells.
Key words: IL-18R • CD4
 
  
 
NK1.1
 
  
 
T cells • Th2 cytokines • CD40 ligand • allergy
 
Introduction
 
IL-18, an IL-1–like cytokine that requires cleavage by
caspase-1 to become active, was originally identified as a
factor that enhances IFN-
 
  
 
production by Th1 cells in the
presence of anti-CD3 Ab plus IL-12 (1, 2). Later studies
have revealed that IL-18 and IL-12 directly and synergisti-
cally induce IFN-
 
  
 
production by Th1 cells, nonpolarized
T cells, B cells, NK cells, macrophages, and dendritic cells
(3–8). However, our recent studies and those of others
have demonstrated that in the absence of IL-12, IL-18 pro-
motes Th2 cytokine production by T cells, basophils, and
mast cells (9–13). In the presence of IL-3, IL-18 stimulates
basophils and mast cells to produce IL-4 and IL-13 even
without Fc
 
 
 
R cross-linkage (9). CD4
 
  
 
T cells cultured
with IL-2 and IL-18, without TCR engagement, express
CD40 ligand (L),
 
*
 
 produce IL-4 and IL-13, and induce B
cells to secrete IgE in vitro (10). Consistent with these find-
ings, the administration of relatively high doses of IL-18,
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Abbreviations used in this paper:
 
 
 
 
 
-GalCer, 
 
 
 
 galactosylceramide; CFSE,
carboxyfluorescein diacetate succinimidyl ester; L, ligand; MFI, mean
fluorescence intensity; Tg, transgenic.T
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Role of NKT Cells in IL-18–induced IgE Production
 
which have the ability to induce Th1 diseases when admin-
istrated with IL-12 to WT mice (14), results in striking in-
creases in serum IgE that are dependent on CD4
 
  
 
T cells,
IL-4, and signal transducer and activator of transcription 6
but are independent of TCR engagement (10). Transgenic
(Tg) mice that overexpress IL-18 or caspase-1 in their kera-
tinocytes (KIL-18Tg and KCASP1Tg, respectively) spon-
taneously produce IgE in an endogenous IL-18–dependent
manner (10, 15, 16). Taken together, these results suggest
that IL-18 promotes allergic disorders, particularly intrinsic
type atopic diseases characterized by the absence of sensi-
tivity to a particular antigen.
Although it is well established that IL-18 stimulates CD4
 
 
 
T cells to produce IL-4 in vivo and in vitro, the CD4
 
  
 
T
cell subset that responds to IL-18 in vivo by inducing IL-4
production and CD40L expression remains unknown. NKT
cells express the NK cell marker NK1.1 and an invariant
TCR V
 
 
 
14-J
 
 
 
281 chain, preferentially associated with a
V
 
 
 
8.2 chain (17). NKT cells are positively selected by the
nonpolymorphic MHC class I–like molecule CD1d (17)
and recognize glycolipids, such as 
 
  
 
galactosylceramide (
 
 
 
-
GalCer) presented by CD1d (18). 
 
 
 
60% of all NKT cells
express CD4 whereas the remaining cells are CD4
 
  
 
CD8
 
 
 
(17). NKT cells exert regulatory functions, which are most
likely mediated by their capacity to promptly release large
amounts of IL-4 and IFN-
 
  
 
upon TCR engagement by
anti-CD3 or NKT cell Ls such as 
 
 
 
-GalCer (19–22). Mod-
ulation of NKT cells may not only determine the outcome
of host immune response, but also be applicable for the
treatment of immunological diseases. Furthermore, it is im-
portant to determine the stimulus that selectively induces
NKT cells to produce Th1 or Th2 cytokines.
Here we demonstrate that IL-18 treatment of mice in-
duces CD40L expression and IL-4 production by NKT
cells in vivo. NKT cell–deficient (CD1d-deficient; CD1d
 
 
 
/
 
 
 
)
mice or conventional CD4
 
  
 
T cell–deficient (class II–defi-
cient; class II
 
 
 
/
 
 
 
) mice fail to produce IgE in response to
injection of IL-18 whereas class II
 
 
 
/
 
  
 
mice reconstituted
with conventional CD4
 
  
 
T cells produce a substantial
amount of IgE. Culturing NKT cells with IL-2 and IL-18,
without TCR engagement, causes a striking increase in
CD40L expression and production of significant amounts
of IL-4, IL-9, and IL-13 by these cells. Although conven-
tional CD4
 
  
 
NK1.1
 
  
 
T cells respond poorly to IL-18 with
relatively modest induction of IL-4 and CD40L, they are
required for IgE production in response to IL-18 in vivo, as
shown by the failure of class II
 
 
 
/
 
  
 
mice reconstituted with
conventional CD4
 
  
 
T cells from IL-4
 
 
 
/
 
  
 
mice to produce
IgE when treated with IL-18. These results indicate that
NKT cells are a critical subset of CD4
 
  
 
T cells that respond
to IL-18 by expression of Th2 cytokines and CD40L in
vivo, and conventional CD4
 
  
 
T cells act as Th cells to-
gether with NKT cells in IL-18–induced IgE responses.
 
Materials and Methods
 
Mice and Reagents.
 
Specific pathogen-free female BALB/c
and C57BL/6 mice, and C57BL/6 class II
 
 
 
/
 
  
 
mice at 8 wk of age
 
were purchased from The Jackson Laboratory. C57BL/6 IL-4
 
 
 
/
 
 
 
mice were obtained from Taconic Farms. Mice Tg for 
 
   
 
TCR
recognizing OVA
 
323–339 
 
(DO11.10; BALB/c genetic background)
were provided by D. Loh (Washington University, St. Louis,
MO). The generation of C57BL/6 CD1d
 
 
 
/
 
  
 
mice was previ-
ously described (23). Recombinant mouse IL-18 and anti–mouse
IL-18R
 
  
 
chain mAb (Y38; reference 24) were provided by Ha-
yashibara Biochemical Laboratories Inc. FITC-anti–mouse CD4
(GK1.5), FITC-anti–mouse CD44 (IM7), FITC-anti–rat IgG1
(RG11/39.4), FITC-anti–mouse IL-4 (BVD4–1D11), CyChrome-
anti–mouse CD4 (RM4-5), biotinylated anti–mouse CD40L,
PE-anti–mouse NK1.1 (PK136), and PE-labeled streptavidin were
purchased from BD Biosciences.
 
Preparation of NKT Cells.
 
Splenic CD4
 
  
 
T cells from
C57BL/6 mice were purified by MicroBeads (anti–mouse CD4,
clone RM4-5; Miltenyi Biotec). The enriched CD4
 
  
 
T cells
were first treated with 10 
 
 
 
g/ml anti-Fc
 
 
 
RII/III for 30 min at
4
 
 
 
C followed by treatment with FITC–anti-CD4 and PE–anti-
NK1.1 for 30 min at 4
 
 
 
C in staining buffer (PBS, 1% FCS). Both
CD4
 
  
 
NK1.1
 
  
 
and CD4
 
  
 
NK1.1
 
  
 
T cells were sorted by using a
fluorescence cell sorter (Elite; Coulter Electronics). Purity of
each population was 
 
 
 
98.5% after reanalysis. In some experi-
ments, CD4
 
  
 
NK1.1
 
  
 
T cells were negatively enriched by deple-
tion of other cell populations from spleen cells. Cell depletion
was performed by treatment with a mixture of FITC–anti-
B220, FITC–anti-CD8, FITC–anti–I-A
 
d
 
, FITC–anti-NK1.1,
and FITC–anti-Fc
 
 
 
RII/III antibodies (BD Biosciences) and sub-
sequent incubation with anti–FITC-coated magnetic beads (Mil-
tenyi Biotec), followed by two rounds of exposure to a magnetic
field. The enriched CD4
 
  
 
NK1.1
 
  
 
T cells were stained with
FITC–anti-CD44 and PE–anti-NK1.1, and CD44
 
high 
 
NK1.1
 
  
 
T
cells were sorted.
 
In Vitro Culture.
 
Sorted CD4
 
  
 
NK1.1
 
  
 
and CD4
 
  
 
NK1.1
 
  
 
T
cells from C57BL/6 mice (10
 
5
 
/0.2 ml/well) were cultured with
medium alone or various combinations of 200 pM IL-2, 10 ng/
ml IL-12, and 50 ng/ml IL-18 for 4 d in RPMI 1640 supple-
mented with 10% FBS, 50 
 
 
 
M 2-ME, 2 mM 
 
l
 
-glutamine, 100
U/ml penicillin, and 100 
 
 
 
g/ml streptomycin. Supernatants
were harvested and tested for IL-4, IL-9, IL-13, and IFN-
 
  
 
con-
tents by ELISA. The collected T cells were also examined for
their expression of CD40L and capacity to induce B cells to pro-
duce IgE by incubation with highly purified B cells as previously
described (10).
 
In Vivo Treatment of Mice.
 
Mice were injected on a daily basis
with PBS buffer or IL-18 (2 
 
 
 
g/day) for 13 d. For adoptive
transfer experiments, class II
 
 
 
/
 
  
 
mice were transferred with 10 
 
 
 
10
 
6 
 
purified CD4
 
  
 
NK1.1
 
  
 
T cells from either WT or IL-4
 
 
 
/
 
 
 
mice intravenously. From the day after cell transfer, mice were
treated daily with 2 
 
 
 
g IL-18 as described above. They were bled
0, 7, 10, and 14 d later and serum IgE, IL-4, and IL-13 were
measured by ELISA. In some experiments, CD4
 
  
 
NK1.1
 
  T cells
from WT mice were labeled with carboxyfluorescein diacetate
succinimidyl ester (CFSE; Molecular Probes, Inc.; reference 25)
and transferred to class II /  mice. Cells containing transferred
cells were stained with PE–anti-CD4 and transferred cells were
identified by their CFSE fluorescence and CD4 expression. The
frequency of repopulated CD4  T cells in class II /  mice was
calculated by (number of CFSE  CD4  cells) / (number of trans-
ferred cells).
Flow Cytometry. To detect IL-4–producing cells from mice
treated with IL-18, total spleen cells derived from C57BL/6 mice
that had been injected with IL-18 for 10 d were first stained with
CyChrome–anti-CD4 and PE–anti-NK1.1 and followed by fixa-T
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tion with 4% (wt/vol) paraformaldehyde in PBS and permeabili-
zation of cell membrane with ice-cold PBS containing 1% FCS
plus 0.1% saponin. Resultant cells were further stained with 0.5
 g FITC-anti–mouse IL-4 or isotype-matched control Ab and
analyzed for their proportion of cytoplasmic IL-4  cells by FACS-
Calibur® (Becton Dickinson). To detect CD40L  cells in mice
treated with IL-18, total spleen cells were stained with FITC–
anti-CD4, PE–anti-NK1.1, and the combination of biotinylated
anti-CD40L and tri-color streptavidin (Caltag), and then analyzed
on a FACSCalibur®.
For determination of IL-18R  chain expression on NKT cells,
after FcR blocking with anti-Fc RII/III, splenic lymphocytes
were incubated with anti–mouse IL-18R  chain mAb or control
rat IgG1 mAb (R3-34) for 30 min at 4 C, followed by FITC-
conjugated anti–rat IgG1 mAb, PE–anti-NK1.1, and Cy-
Chrome-anti–mouse CD4 for 30 min at 4 C in staining buffer.
Samples were analyzed on a FACSCalibur®.
Results
CD1 /  Mice Are Defective in the Production of Th2 Cyto-
kines and IgE in Response to IL-18 Administration. IL-18
treatment of BALB/c mice induces IgE in a CD4  T cell–
dependent manner (10). Consistent with our previous report
(10), this IgE response is not associated with induction of
Th2 cells (not depicted), suggesting that TCR engagement
might not be required for IgE induction in IL-18–injected
mice. To further substantiate this observation that IgE re-
sponse is independent of TCR engagement by endogenous
Ags, we examined the capacity of BALB/c mice expressing
transgene-encoding TCR for OVA peptide (DO11.10
mice) to produce IgE in response to IL-18. These mice re-
ceived daily injections of IL-18 (2  g/day) for 13 d. Like
normal BALB/c mice, they produced IgE in response to this
treatment (Fig. 1 A), although this IL-18 treatment again did
not induce Th2 response (not depicted). Furthermore, this
IL-18–induced IgE production was entirely resistant to cy-
closporin A treatment (not depicted), further excluding the
involvement of TCR-mediated T cell activation in this T
cell–dependent IgE response. To identify the IL-18–respon-
sive T cells that are relevant in IL-18–induced IgE response,
we compared the capacity of C57BL/6 and C57BL/6 back-
ground CD1 /  mice lacking CD4  NK1.1  T cells (23) to
produce IgE in response to IL-18. As shown in Fig. 1 B, IL-
18 caused a striking increase in serum IgE levels in WT mice
but not in CD1 /  mice. Furthermore, administering IL-18
to WT mice caused the production of a significant amount
of IL-4 and IL-13 whereas CD1 /  mice produced no IL-4
and diminished amounts of IL-13 (Fig. 1, C and D). These
results suggest that CD4  NK1.1  T cells produce both IL-4
and IL-13 in response to IL-18.
NKT Cells Produce IL-4 and Express CD40L in Response
to In Vivo Treatment with IL-18. To determine the roles
of NKT cells in IL-18–induced IgE response, we directly
tested whether CD4  NK1.1  T cells produce IL-4 and in-
crease CD40L expression when WT mice are injected with
IL-18. As shown in Fig. 2 A, CD4  NK1.1  T cells ob-
tained from IL-18–injected mice, compared with PBS-
injected mice, showed a significant increase (P   0.01) in
the proportion of T cells producing IL-4 ex vivo (7.1%). In
contrast, few, if any, CD4  NK1.1  T cells contained cyto-
Figure 1. CD1 /  mice fail to produce IgE and IL-4 in
response to in vivo treatment with IL-18. (A–D) BALB/c,
BALB/c background DO11.10 Tg, C57BL/6, and
C57BL/6 background CD1 /  mice (five mice per group)
were injected daily with IL-18 (2  g/day) for 13 d. Mice
were bled on days 0, 7, 10, and 14 and serum IgE (A and
B), IL-4 (C), and IL-13 (D) were measured by ELISA. Re-
sults are geometric means   SD. *,  10 pg/ml.T
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plasmic IL-4. Similarly, CD4  NK1.1  T cells in IL-18–
injected WT mice showed a significant increase (P   0.01)
in the proportion of CD40L-expressing T cells (Fig. 2 B).
Although IL-18 also caused an increase in the proportion
of CD4  NK1.1  T cells that expressed CD40L, the fre-
quency of positive cells was significantly less than that
among the CD4  NK1.1  T cells.
IL-18R  Chain Expression on NKT Cells. The respon-
siveness of CD4  NK1.1  T cells to IL-18 suggested that
these cells express IL-18R constitutively. We compared
the expression of IL-18R  chain on CD4  NK1.1  and
CD4  NK1.1  T cells by flow cytometric analysis using
anti–IL-18R   chain mAb. NK cells (CD4  NK1.1high),
which express high levels of IL-18R  chain (24), were in-
cluded as positive controls. Freshly prepared splenic CD4 
NK1.1  T cells (Fig. 2 C, R2) constitutively express high
levels of IL-18R   chain (mean fluorescence intensity
[MFI]: 11.0) whereas CD4  NK1.1  T cells (Fig. 2 C, R1)
express only low levels (MFI: 3.9). Consistent with previ-
ous reports of ours (24) and others (11), NK cells (Fig. 2 C,
R3) constitutively express high levels of IL-18R  chain.
They produce IL-13 but not IL-4 upon IL-18 stimulation
in vitro (not depicted).
IL-18 Stimulates NKT Cells to Produce IL-4, Express
CD40L, and Enhance IgE Production by B Cells. To fur-
ther substantiate the capacity of CD4  NK1.1  and CD4 
NK1.1  T cells to produce IL-4 and express CD40L in re-
sponse to IL-18, we sorted CD4  NK1.1  and CD4 
NK1.1  T cells and stimulated them with 200 pM IL-2
and/or 50 ng/ml IL-18 for 4 d. As shown in Fig. 3 A,
CD4  NK1.1  T cells cultured with IL-18 and IL-2 pro-
duced significant amounts of IL-4 and IL-13 whereas con-
ventional CD4  NK1.1  T cells produced little IL-4 and
small amounts of IL-13. We also found that IL-18 plus IL-2
stimulates CD4  NK1.1  but not CD4  NK1.1  T cells to
produce IL-9 (Fig. 3 A). CD4  NK1.1  T cells cultured
with IL-18 and IL-2 produced modest amounts of IFN- 
(249 pg/ml), far less than that (5,381 pg/ml) stimulated by
IL-18 and IL-12 (not depicted).
As shown in Fig. 3 B, IL-2 or IL-18 alone substantially
increased CD40L expression on CD4  NK1.1  T cells
(46.1 and 39.7%), but the combination caused profound
induction (94.2%). In contrast, the same treatment of
CD4  NK1.1  T cells only moderately induced CD40L,
suggesting that CD4  NK1.1  T cells are the major targets
of IL-18.
We also tested the capacity of CD4  NK1.1  T cells and
CD4  NK1.1  T cells stimulated with IL-2 and IL-18 for
4 d to induce IgE in resting B cells in vitro. IL-2 plus IL-
18–stimulated CD4  NK1.1  T cells were able to induce
B cells to secrete IgE whereas conventional CD4  NK1.1 
T cells failed (Table I). Taken together, these results indi-
cate that NKT cells constitutively expressing IL-18R 
chain are a crucial subset of CD4  T cells that respond to
IL-18 by producing IL-4 and expressing CD40L, which in
combination, induce IgE production by B cells both in
vivo and in vitro.
NKT Cells but Not Previously Activated CD4  NK1.1  T
Cells Produce IL-4 in Response to IL-18. In Fig. 3, we
demonstrated that NKT cells but not CD4  NK1.1  T
cells are highly responsive to IL-18. To determine if the in-
duction of Th2 cytokines and CD40L after IL-18 is a
unique property of NKT cells or a property of all previ-
ously activated or memory T cells, we compared IL-18 re-
sponsiveness of NKT cells to that of previously activated
Figure 2. NKT cells produce IL-4 and express CD40L in response to
in vivo treatment with IL-18. C57BL/6 mice were injected daily with
IL-18 (2  g/day) or PBS for 10 d (four mice per group). Intracellular IL-4
(A) or CD40L staining (B) of CD4  NK1.1  and CD4  NK1.1  T cells
was performed as described in Materials and Methods. Representative
data are shown from four independent mice. The percentage shown rep-
resents the proportion of cells positive for cytoplasmic IL-4. Results are
geometric means   SD. *, P   0.01. (C) Freshly prepared splenic cells
from C57BL/6 mice were analyzed for expression of CD4 and NK1.1 by
flow cytometry. IL-18R   chain expression on CD4  NK1.1  (R1),
CD4  NK1.1  (R2), and CD4  NK1.1high (R3) cells was analyzed as de-
scribed in Materials and Methods. The number shown represents the MFI
of IL-18R  chain staining.T
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conventional CD4  T cells. For this purpose, we used
CD44high CD4  T cells as a control population. Before
comparison, we examined the expression of CD44 on total
CD4  T cells, CD4  NK1.1  T cells, and CD4  NK1.1  T
cells obtained from normal C57BL/6 mice. As shown in
Fig. 4 A, almost all freshly prepared CD4  NK1.1  T cells
(R2) expressed high levels of CD44 whereas only 12.9 and
21.6% of CD4  NK1.1  T cells (R3) and total CD4  T
cells (R1) expressed CD44, respectively.
Because a substantial proportion of CD44high CD4  T ex-
press NK1.1 T cells, we compared IL-18 responsiveness of
NKT cells to that of CD44high NK1.1  CD4  T cells or
CD44int NK1.1  CD4  T cells. As NKT cells sometimes
lose their NK1.1 expression during or after stimulation (26),
we sorted CD44high NK1.1  CD4  T cells from splenic
CD4  T cells, already depleted of other cell populations,
particularly NKT cells (refer to Materials and Methods).
We also sorted CD44int  NK1.1   T cells and CD44high
NK1.1  CD4  T cells (NKT cells) from total CD4  T cells.
We stimulated these three populations with IL-2 and/or
IL-18. Consistent with the results shown in Fig. 3 A, only
NKT cells produced both IL-4 and IL-13 in response to IL-2
plus IL-18 (Fig. 4 C). These results support our conclusion
that NKT cells but not previously activated conventional T
cells have the capacity to induce IgE from B cells.
Figure 3. NKT cells produce IL-4, IL-9, and IL-13
and express CD40L in vitro in response to IL-18.
Sorted CD4  NK1.1  and CD4  NK1.1  T cells (105/
0.2 ml/well) from C57BL/6 mice were cultured with
various combinations of 200 pM IL-2 and 50 ng/ml
IL-18. After 4 d of culture, supernatants were harvested
and tested for IL-4, IL-9, IL-13, and IFN-  contents
by ELISA (A) and surface expression of CD40L was
analyzed by flow cytometry (B). The percentage
shown represents the proportion of CD40L   cells
among CD4  T cells. Results are geometric means  
SD. *,  10 pg/ml; **,  40 pg/ml.
Table I. Induction of IgE Production by B Cells Cocultured with 
IL-18 and IL-2–stimulated NKT Cells or Conventional CD4 
T Cells
Cells Culture conditions IgE (ng/ml)
CD4  NK1.1  T cells medium  10
IL-2 plus IL-18  10
CD4  NK1.1  T cells medium  10
IL-2 plus IL-18 90.1   3.7
CD4  NK1.1  and CD4  NK1.1  T cells (105/0.2 ml/well) from
C57BL/6 mice were cultured with medium alone or 50 ng/ml IL-18
and 200 pM IL-2. After 4 d of culture, freshly purified C57BL/6 splenic
B cells (105/0.2 ml/well) were added with 10  g/ml anti–IFN- 
antibody. After an additional 10 d of incubation, supernatants were
harvested and IgE contents were measured by ELISA. Results are
geometric means   SD.T
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CD4  NK1.1  T Cells Are Required in IL-18–induced IgE
Responses. Although conventional CD4  NK1.1  T cells
responded poorly to IL-18 in vivo and in vitro with rela-
tively modest induction of IL-4 and CD40L, these results
leave open the question of whether conventional CD4  T
cells are also required for the observed effect of IL-18 on
IgE production. Thus, we tested IL-18 responsiveness of
class II /  mice expressing almost the same number of
CD4  NK1.1  T cells as were expressed by WT mice, al-
though CD4  T cells constituted only 4 to 5% of their
spleen cells (Fig. 5 A; reference 20). As shown in Fig. 5 B,
class II /  mice completely failed to demonstrate induction
of IgE in response to IL-18 treatment. However, class II / 
mice reconstituted with conventional CD4  T cells from
WT mice mounted a small but significant IgE response to
IL-18 (Fig. 5 C) whereas those mice reconstituted with
conventional CD4  T cells from IL-4 /  mice failed to do
so in response to IL-18 (Fig. 5 C). Compared with WT
mice, class II /  mice reconstituted with CD4  T cells
showed weak IgE responses, suggesting that host spleen
was only partially repopulated. Indeed, only 0.94, 1.58, and
0.64% of transferred conventional T cells were repopulated
at days 3, 7, and 10, respectively (Fig. 5 D). These results
provide direct evidence that IL-4–producing conventional
CD4  T cells are needed for IgE production by B cells.
Discussion
Here we show that the administration of IL-18 results in
increases in serum levels of IgE, IL-4, and IL-13 in normal
mice but not in CD1 /  mice, which lack NKT cells (Fig.
1). In addition, NKT cells, which are strongly positive for
the IL-18R  chain, produce IL-4, IL-9, and IL-13 and ex-
press CD40L in response to IL-18 plus IL-2 in the absence of
TCR engagement (Figs. 2 and 3). Furthermore, NKT cells
that are stimulated with IL-18 and IL-2 for 4 d promote class
Figure 4. Previously activated CD4  NK1.1  T
cells fail to produce IL-4 in response to IL-18. (A)
Freshly prepared CD4  cells from C57BL/6 mice
were analyzed for expression of CD44 gated on to-
tal CD4 (R1), CD4  NK1.1  (R2), and CD4 
NK1.1  (R3) T cells by flow cytometry. (B) Total
CD4  T cells were negatively depleted of NKT
cells as well as other cell populations and then posi-
tively sorted for CD44high NK1.1  T cells (R1).
CD44int NK1.1  T cells (R2) and NKT cells (R3)
were positively sorted from total CD4  T cells. (C)
Sorted CD4  CD44high NK1.1 , NKT, and CD4 
CD44int NK1.1  T cells (105/0.2 ml/well) were
cultured with various combinations of 200 pM IL-2
and 50 ng/ml IL-18. After 4 d of culture, superna-
tants were harvested and tested for IL-4 and IL-13
by ELISA.T
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switching to IgE in B cells in vitro (Table I). However, class
II /  mice, which have NKT cells but lack conventional T
cells, fail to produce IgE in response to IL-18 treatment, sug-
gesting the importance of conventional T cells in IL-18–
induced IgE response (Fig. 5). Indeed, these mice were able
to produce IgE after reconstitution with conventional T cells
from WT but not from IL-4 /  mice. Taken together, these
results demonstrate that NKT cells are relevant cells for IL-
18–induced IL-4 production and suggest that they recruit
the action of conventional T cells in the induction of IgE.
In atopic individuals, it is well known that allergens give
rise to a polarization to Th2 responses and that enhanced se-
cretion of IL-4 promotes IgE production (27). Allergen
binding to IgE cross-links Fc R on basophils and mast cells,
which causes them to produce IL-3, IL-4, IL-5, IL-9,
IL-13, and a variety of chemical mediators, most notably
histamine (28). The combination of these products induces
allergic inflammation, highlighting the importance of IgE for
activating basophils and mast cells. Thus, we could designate
this IgE-dependent allergic disease as “acquired type allergic
response.” However, we have recently demonstrated an al-
ternative, IgE-independent activation pathway of mast cell/
basophil (“innate type allergic response”; reference 16). IL-
18 in combination with IL-3 directly stimulates these cells
to produce IL-4, IL-13, and histamine in an IgE-indepen-
dent manner (9). IL-18 also stimulates CD4  T cells to pro-
duce IL-4 and express CD40L, which can induce in vitro
class switching to IgE in B cells in an Ag-independent man-
ner (10). Our previous study also demonstrated that IL-18–
treated mice or IL-18–producing caspase-1 Tg mice express
high serum levels of IgE, which is CD4  T cell–, IL-4–, and
signal transducer and activator of transcription 6–dependent,
but Th2 cell independent (10). Here we show that IL-18
stimulates IgE production in OVA-specific TCR Tg mice
without OVA administration (Fig. 1 A). Furthermore, we
found that this IgE response is Ag nonspecific and resistant
to cyclosporin A treatment. However, IL-18 is not neces-
sarily essential for induction of IgE response because like
WT mice, IL-18–deficient mice generate a Th2 response
and produce IgE when inoculated with the helminth Nip-
postrongylus brasiliensis (unpublished data). Thus, N. brasilien-
sis–induced Th2 responses, which require TCR engage-
ment, can be generated in the absence of IL-18. These
results indicate that IgE response to antigen using the TCR
is possibly not affected by blocking IL-18 as a therapeutic
strategy but is susceptible to the treatment with cyclosporin
A. In other words, IL-18–induced IgE responses become
apparent only in the absence of TCR engagement. Thus,
IL-18 may induce allergic disorders, particularly intrinsic
atopic diseases characterized by the absence of particular al-
lergen-specific IgE. Our results suggest that it is importance
to determine whether observed IgE response is dependent
on TCR and/or IL-18–mediated signaling.
The novel lymphoid lineage, NKT cells, which expresses
both NK receptors and TCR encoded by the V 14 and
J 281 gene segments, has been suggested to play an impor-
tant role in the regulation of immune responses (17). Cyto-
kines such as IL-12 can stimulate NKT cells to release IFN- 
and exhibit natural cytotoxity (29, 30). Recent studies
demonstrated that NKT cells could transactivate NK cells
via IFN-  production upon stimulation with CD1d-bound
glycolipid L ( -GalCer; reference 18). This IFN-  produc-
tion by NKT cells in response to  -GalCer is predomi-
nantly mediated by IL-12 produced by dendritic cells (31).
Moreover,   -GalCer–stimulated NKT cells inhibit anti-
gen-induced allergic responses by production of IFN- 
Figure 5. Transfer of conventional CD4  T cells from WT mice par-
tially reconstitutes IgE production by class II /  mice injected with IL-18.
(A) Frequency of CD4  NK1.1  T cells in total spleen cells (top) and
CD4-enriched spleen cells (bottom) from C57BL/6, CD1 / , and class
II /  mice. Percent of cells in selected quadrants are indicated. C57BL/6
and class II /  mice received either nothing (B) or 107 CD4  NK1.1  T
cells from WT or IL-4 /  mice (C; five mice per group) and were in-
jected daily with IL-18 (2  g/day) for 13 d. Mice were bled on days 0, 7,
10, and 14 and serum IgE was measured by ELISA. (D) Class II /  mice
(three mice per group) received an intravenous injection of 107 CFSE-
labeled CD4  T cells from C57BL/6 mice. Spleen cells were isolated
from recipients at various times after transfer and transferred cells were
identified by CSFE fluorescence as described in Materials and Methods.T
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(32). However, NKT cells also exert regulatory functions,
most likely through their capacity to promptly release
large amounts of IL-4 upon stimulation with anti-CD3 or
 -GalCer, thus promoting the acquisition of a Th2 pheno-
type (19–22). Therefore, NKT cells can promote Th1 re-
sponses in certain situations and Th2 responses in others.
The data presented here show that among CD4  T cells,
NKT cells have the unique capacity to respond to IL-18 by
IL-4 production and CD40L up-regulation and directly help
B cells produce IgE in vitro and in vivo without antigenic
stimulation. However, our studies with class II /  mice re-
veal that conventional CD4  T cells are also required for the
observed effect of IL-18 on IgE production (Fig. 5). Class
II /  mice reconstituted with conventional CD4  T cells
from WT mice but not from IL-4 /  mice mounted a small
but significant IgE response to IL-18 (Fig. 5 C), suggesting
that conventional T cells participate in IgE induction by se-
creting a small amount of IL-4. However, this IgE produc-
tion in WT CD4  T cell reconstituted mice failed to in-
crease beyond day 10 after IL-18 administration. We suspect
that the failure to completely reconstitute IL-18–induced
IgE responses in these animals is due to incomplete repopu-
lation of CD4  T cells in class II /  hosts (Fig. 5 D). We
could increase the number of repopulated cells by increasing
the number of transferred cells, although we could not in-
crease repopulation rate (unpublished data). Thus, in the ab-
sence of class II expression, CD4  T cells may not survive
efficiently and are unable to completely reconstitute IgE
production. Nevertheless, our finding indicates that IL-4
production by both NKT and conventional CD4  T cells is
critical for IL-18–induced IgE production. However, as
NKT cells and conventional T cells produce large and small
amounts of IL-4, respectively, the precise role of IL-4 from
conventional T cells in B cell activation remains uncertain.
Furthermore, we do not know the appropriate ratio of NKT
cells to conventional T cells in effective B cell IgE responses.
We have shown that KIL-18Tg and KCASP1Tg mice,
which overexpress mature IL-18 or caspase-1 gene, respec-
tively, in keratinocytes, spontaneously produce IgE in an
endogenous IL-18–dependent manner (10, 15, 16). Inter-
estingly, our recent examination of KCASP1Tg mice re-
vealed that they exhibited a two- to threefold increase in
splenic NKT cells, although short-term in vivo treatment
with IL-18 did not affect the number of splenic NKT cells
(unpublished data). These increases in the proportion of
splenic NKT cells and serum IgE levels in KCASP1Tg
mice are somewhat similar to that in the V 14-J 281 Tg
mice established by Bendelac et al. (33). These V 14-
J 281 Tg mice exhibit a selective increase in serum IgE
(sixfold above controls on average) and IgG1 (twofold
above controls). Here, we have provided strong evidence
that CD1d-restricted NKT cells are critically important for
the induction of IgE in response to IL-18. However, as
NKT cells that express TCR other than V 14-J 281 TCR
are also selected by CD1d (34), it remains possible that such
nonclassical NKT cells also contribute to the IL-18–induced
IgE response. Future studies with J 281 /  mice should be
able to resolve this issue.
Recently, Leite-de-Maraes et al. (35) have reported that
IL-18 enhances IL-4 production by L-activated NKT cells
but not by conventional T cells. Thus, IL-18 enhances
anti-CD3 Ab– or  -GalCer–induced IL-4 production by
NKT cells. However, IL-18 also enhanced IFN-  produc-
tion by NKT cells stimulated with anti-CD3 or  -GalCer.
These results suggest that IL-18 exerts its action on IL-4
production by NKT cells by amplifying the signaling path-
way initiated by TCR/CD3 cross-linkage or cognate L
 -GalCer. In sharp contrast, our results reveal that IL-18
and IL-2 synergistically and directly exert IL-4 and CD40L-
inducing activities on NKT cells even in the absence of
TCR engagement. Furthermore, these activated NKT cells
in collaboration with IL-4–producing conventional T cells
can induce class switching to IgE in B cells, indicating a new
function of NKT cells in innate immunity. These findings
suggest that IL-18 and NKT cells might be potential targets
in the effort to develop agents that regulate Th2-indepen-
dent allergic disorders as innate type allergic response. Fur-
thermore, as IL-18 predominantly enhances production of
Th2 cytokines both in vitro and in vivo, injection of IL-18
might be promising for the treatment of Th1 diseases such
insulin dependent diabetes mellitus.
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